Johnson--Johnson-COVID-19-Vaccine-Updates Johnson & Johnson COVID-19 Vaccine

​​​​Note: This guidance is no longer in effect and is for historical purposes only.​​

Johnson & Johnson COVID-19 Vaccine

Get the Facts on COVID-19 Vaccines, Boosters, and Additional Doses


On April 24, the Western States Scientific Safety Review Workgroup concluded the Johnson & Johnson vaccine is safe and effective and recommended resuming use of the vaccine for all eligible Californians.

On April 23, the U.S. Food and Drug Administration (FDA) lifted its pause on the use of the Johnson & Johnson vaccine, following a review by a federal vaccine safety review panel.
Clinics can immediately resume administering the vaccine if they have appropriate in-language education materials available to inform conversations with vaccine recipients regarding benefits, risks, and available vaccine options.  ​California has prepared fact sheets about the vaccine to inform conversations between health care providers and vaccine recipients.
In April, the CDC and FDA recommended a temporary pause in the use of the Johnson & Johnson COVID-19 vaccine out of an abundance of caution, and California followed that temporary pause. With nearly 8 million doses administered nationally, there have been at least 15 reported cases of a rare and severe type of blood clot, seen in combination with low levels of blood platelets. These symptoms occur 6 to 15 days after vaccination.
If you have received the Johnson & Johnson COVID-19 vaccine, and develop shortness of breath, chest pain, leg swelling, persistent abdominal pain, severe and persistent headaches or blurred vision, or easy bruising/tiny blood spots under the skin beyond the site of the injection within three weeks after vaccination, contact your healthcare provider, or seek medical care.

For more information about the adverse effects, and what to do if you are experiencing symptoms, please contact your healthcare provider.

Additional Resources